Imsidolimab
Generalized Pustular Psoriasis (GPP)
BLA FiledFDA Application Under Review
Key Facts
Indication
Generalized Pustular Psoriasis (GPP)
Phase
BLA Filed
Status
FDA Application Under Review
Company
About Vanda Pharmaceuticals
Vanda Pharmaceuticals is a publicly traded biopharma company with a mission to 'innovate in the service of people's pursuit of happiness' by developing targeted therapies for CNS and sleep disorders. Its core strategy integrates genetics and genomics into all stages of drug development to enhance clinical trial success and commercial positioning. Key achievements include the FDA approvals of Fanapt® for schizophrenia and Hetlioz® for Non-24, with recent milestones including the 2026 approval of BYSANTI™ and a landmark FDA hearing for Hetlioz® in Jet Lag Disorder.
View full company profileTherapeutic Areas
Other Generalized Pustular Psoriasis (GPP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Spesolimab (Spevigo) | Boehringer Ingelheim | Marketed |